Market TodayThemes and Stocks SummaryThematic Stock SearchCrypto SummaryFAQAbout
NVTA - Invitae Corp
-0.13(-4.38%)9:00:01 PM 12/2/2022
Invitae Corporation, a medical genetics company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. It offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, metabolic conditions, and rare diseases; prenatal and perinatal genetic tests; and non-invasive prenatal screening products. The company also provides preimplantation and carrier screening for inherited disorders; products for prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders; a platform for collecting, curating, coordinating, and delivering data from patients and clinicians; and CancerGene Connect, a platform for collecting and managing genetic family histories to deliver personalized genetic risk information. It serves patients, healthcare providers, and biopharma and advocacy partners. Invitae Corporation has a collaboration with Gene Therapies Ltd. for the detection of lysosomal storage disorders in children; and a research collaboration with Pacific Biosciences of California, Inc. for the investigation of clinically relevant molecular targets for use in the development of advanced diagnostic testing for epilepsy. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was founded in 2010 and is headquartered in San Francisco, California.
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 


Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

No summary
Related Topics

Related Peers

Stock news

    Invitae Launches Rare Patient Network for Pediatric Patients With Rare Neurodevelopmental Diseases

    Invitae (NYSE: NVTA), a leading medical genetics company, today announced the launch of the Rare Patient Network expanding Invitae's Ciitizen platform to all patients with pediatric epilepsy and/or developmental delay with plans to include other conditions in the coming months. By engaging with a broader community, Invitae, a leader in the rare pediatric neurodevelopmental field, aims to create value for significantly more patients with rare diseases.

    Is Invitae in Danger of Running Out of Money?

    Invitae (NYSE: NVTA) is a genetic testing company that's in its early growth stages, so shareholders should expect to take on some risk with a stock like this. Or could it be a good long-term investment for growth investors to buy and hold? A big problem with Invitae is that it is burning through lots of cash.

    Why Shares of Invitae Rose 11% on Tuesday

    Shares of medical genetics testing company Invitae (NYSE: NVTA) rose 11% on Tuesday. Invitate didn't have any announcements on Tuesday, though it is presenting research this week in Nashville, Tennessee, at the National Society of Genetic Counselors conference. Invitae reported revenue of $133.5 million, up 16.7%, year over year.

    More Likely to 5X First: Teladoc vs. Invitae

    Two stocks that could climb fivefold if they make progress toward their goals are Teladoc Health (NYSE: TDOC) and Invitae (NYSE: NVTA). Teladoc and Invitae shares both have lost more than 70% this year. Teladoc disappointed investors with two massive noncash goodwill impairment charges linked to an acquisition.

    Invitae Showcases Advances in Medical Genomics at the National Society of Genetic Counselors (NSGC) 41st Annual Conference

    Researchers from Invitae (NYSE: NVTA), a leading medical genetics company, are presenting research next week at the National Society of Genetic Counselors (NSGC) 41st Annual Conference in Nashville enabling the progress of the science and practice of genetics in patient care. In addition to its research presentations, the company will present the Heart of Genetic Counseling Award, which recognizes excellence in the field of genetic counseling.

    Invitae Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS Lags

    Invitae ( NYSE:NVTA ) Third Quarter 2022 Results Key Financial Results Revenue: US$133.5m (up 17% from 3Q 2021). Net...

    Why Invitae Stock Is Crushing It Today

    Invitae (NYSE: NVTA) stock was absolutely crushing it on Wednesday, with its shares skyrocketing 19.4% higher as of 11:11 a.m. ET. The huge gain came after the medical genetics company announced its third-quarter results following the market close on Tuesday. Invitae posted a net loss of $301.2 million, or $1.27 per share, based on generally accepted accounting principles (GAAP).

    Invitae (NVTA) Q3 2022 Earnings Call Transcript

    Hello, everyone, and thank you for joining the Invitae's third quarter 2022 financial results conference call. Joining us today are president and CEO, Ken Knight; and our CFO, Roxi Wen. Before we begin, I'd like to remind you the various remarks that we make on this call that are not historical, including those about our vision and business model, the company's strategic business realignment, future financial and operating results, expectations of future growth and reduction in burn rate and f...

    Invitae (NVTA) Reports Q3 Loss, Tops Revenue Estimates

    Invitae (NVTA) delivered earnings and revenue surprises of 28.81% and 0.55%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

    Invitae Reports Third Quarter 2022 Financial Results

    Invitae (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the third quarter ended September 30, 2022.